Biological Sciences Platform
Christina R. Lee has not added Biography.
If you are Christina R. Lee and would like to personalize this page please email our Author Liaison for assistance.
Friend virus-induced erythroleukemias: a unique and well-defined mouse model for the development of leukemia.
Anticancer research May-Jun, 2003 | Pubmed ID: 12894591
Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
Cancer research Aug, 2005 | Pubmed ID: 16103050
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Cancer research Apr, 2006 | Pubmed ID: 16585158
On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Aug, 2006 | Pubmed ID: 16921064
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Science (New York, N.Y.) Sep, 2006 | Pubmed ID: 16990548
Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia.
Blood Mar, 2007 | Pubmed ID: 17053052
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.
Proceedings of the National Academy of Sciences of the United States of America Oct, 2007 | Pubmed ID: 17942672
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Cancer research Jan, 2008 | Pubmed ID: 18199548
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines.
Molecular cancer therapeutics Oct, 2008 | Pubmed ID: 18852148
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer cell Mar, 2009 | Pubmed ID: 19249681
Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2009 | Pubmed ID: 19276250
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research Aug, 2009 | Pubmed ID: 19671869
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.
Cancer research Sep, 2009 | Pubmed ID: 19738068
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research Oct, 2009 | Pubmed ID: 19825954
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Neoplasia (New York, N.Y.) Mar, 2010 | Pubmed ID: 20234820
Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis.
PloS one , 2013 | Pubmed ID: 23967178
Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Breast (Edinburgh, Scotland) Aug, 2013 | Pubmed ID: 24074794
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved